MedTrace Logo

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

NCT00690911 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-11-06

No results posted yet for this study

Summary

The purpose of the study is to see if Humira is effective and safe in the treatment of sarcoidosis.

Conditions

  • Sarcoidosis

Interventions

DRUG

adalimumab

40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.

Sponsors & Collaborators

  • Wake Forest University

    lead OTHER

Principal Investigators

  • Joseph Jorizzo, MD · Wake Forest University Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690911 on ClinicalTrials.gov